AH-001 / AnHorn Medicines - LARVOL DELTA

Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery. (PubMed, J Med Chem) - "This miniperspective highlights key advances in the development of topical PROTACs, exemplified by AH-001 and GT20029, androgen receptor degraders, both in clinical trials for androgenetic alopecia, with GT20029 also evaluated for acne. Despite this progress, topical PROTACs face some challenges, such as optimizing the stability, tissue penetration, and selective target engagement under physiological conditions. We conclude by outlining strategic directions that could accelerate the clinical translation of this emerging therapeutic modality."

Journal • Review • Acne Vulgaris • Alopecia • Dermatology • Immunology • Ophthalmology • Targeted Protein Degradation • AR

Inactivation of RhoA for Hypertension Treatment Through the TRPV4-RhoA-RhoGDI1 Axis. (PubMed, Circulation) - "TRPV4 and RhoGDI1 knockdown attenuated AH001's inhibition of VSMC contraction and phenotypic switching to myofibroblasts. This study revealed a novel mode of RhoA signaling inhibition targeting the TRPV4-RhoA-RhoGDI1 axis, offering new insights for future antihypertensive drug development and proposing innovative strategies for targeting challenging Rho GTPases."

Journal • Cardiovascular • Hypertension • GDI1 • MRTFA • RHOA

Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: AnHorn Medicines Co. Ltd.

New P1 trial • Alopecia • Dermatology • Immunology